On August 27, 2018, Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) filed comments to the NIH regarding the prospective grant of two separate exclusive licenses to Sinotau Pharmaceutical Group and Molecular Targeting Technologies, Inc. (MTTI),… Continue Reading
On 24 May 2022, I delivered the following constituency statement on behalf of Knowledge Ecology International, Health Action International, Oxfam, and Public Services International on the following topic: “16.2 – Strengthening WHO preparedness for and response to health emergencies” at… Continue Reading
On Wednesday May 11, 2022, the National Institutes of Health (NIH) was asked about Xtandi and march-in rights during a Congressional hearing. The House Appropriations Committee held a hearing on the FY2023 Budget Request for the NIH, and Representative Mark… Continue Reading
On April 28, 2022, Knowledge Ecology International (KEI) provided comments on the latest National Institutes of Health (NIH) Federal Register notice concerning licensing, the “Prospective Grant of an Exclusive Patent License: Development of Diagnostic for Imaging and Early Detection of… Continue Reading
ACTIV The National Institutes of Health (NIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership, to develop treatments and vaccines. Coordinated by the Foundation for the National Institutes of Health (FNIH), with the NIH and sibling agencies in the… Continue Reading
These are the additional comments to the WHO Public Hearing on a possible WHO treaty or other instrument on pandemic preparedness and response (KEI also provided oral testimony at the hearing, and filed earlier comments here). Luis Gil Abinader –… Continue Reading
Knowledge Ecology International (KEI) filed comments with the National Institutes of Health (NIH) on March 16, 2022 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies (CAR-T) That are Specific to… Continue Reading
(More on this topic here: https://www.keionline.org/xtandi2021) On February 24, 2022, Senators Thom Tillis and Marsha Blackburn sent a letter to HHS Secretary Xavier Becerra (PDF copy). The letter refers to “petitions to march-in on a pharmaceutical product purely based on… Continue Reading
This is a letter from the three prostate cancer patient petitioners to HHS Secretary Becerra and Acting NIH Director Tabak, regarding the February 9, 2020 statement by Astellas on the Bayh-Dole march in and government rights case. The patient’s letter… Continue Reading
2016-Mar25-email-Re-Dir-Sig-Response-March-In-Letter 2016-Dec18-Email-Chain-Re-Reasonable-Pricing-Clauses 2016-Dec24-Email-Seeking-Help-Re-NCI-Criticism-Response 2016-Dec25-Email-Seeking-Help-NCI-Rebuttal 2016Mar30-Email-Sen-Sanders-Letter 2016Apr26-Email-Nader-Response 2016Jun27-Email-re-March-in Process 2017-Jan3-Email-Re-Help-NCI-Rebuttal 2017Jan5-Email-Regarding-Kite-License-Applicants 2017Apr24-Email-Chain-Re-Xtandi-Appeal 2017Nov20-email-helping-Allen 2017-Dec7-Email-Re-Placing-Op-Ed 2019Apr16-email-CAR T-information
Senators Elizabeth Warren (D-MA) and Angus King (I-ME) and Representative Lloyd Doggett (D-TX) wrote Secretary of HHS Xavier Becerra on February 17, 2022, urging him to move forward with the march-in petition by Robert Sachs, Clare Love and Eric Sawyer,… Continue Reading